Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Myotonic Dystrophy Type 1
NCT05532813Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liquid metformin (Aspargo Labs) in myotonic dystrophy type 1 (DM1), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2024; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT05532813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532813.